Y Q Xiong
Overview
Explore the profile of Y Q Xiong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-de-la-Maria C, Xiong Y, Pericas J, Armero Y, Moreno A, Mishra N, et al.
Antimicrob Agents Chemother
. 2017 Mar;
61(5).
PMID: 28264848
Among the viridans group streptococci, the group is the most common cause of infective endocarditis. These bacteria have a propensity to be β-lactam resistant, as well as to rapidly develop...
2.
Xiong Y, Zhou W, Li Q, Cao Q, Tang T, Wang D, et al.
Sci Rep
. 2015 Aug;
5:12766.
PMID: 26238932
The La2/3Ba1/3MnO3 film is deposited in a CMOS-compatible Pt/Ti/SiO2/Si substrate with the oxygen pressure of 10 Pa for investigating magnetoelectric effect. Bipolar resistive switching effect with excellent endurance and retention...
3.
Zhou W, Li Q, Xiong Y, Zhang Q, Wang D, Cao Q, et al.
Sci Rep
. 2014 Nov;
4:6991.
PMID: 25384967
The electric field manipulation of magnetic properties is currently of great interest for the opportunities provided in low-energy-consuming spintronics devices. Here, we report the effect of electric field on magnetic...
4.
Luo G, Spellberg B, Gebremariam T, Lee H, Xiong Y, French S, et al.
Eur J Clin Microbiol Infect Dis
. 2013 Dec;
33(5):845-51.
PMID: 24292099
Iron acquisition is a virulence factor for Staphylococcus aureus. We assessed the efficacy of the iron chelator, deferasirox (Def), alone or in combination with vancomycin (Van) against two methicillin-resistant S....
5.
Xiong Y, Yeaman M, Bayer A
Drugs Today (Barc)
. 2003 Jul;
36(8):529-39.
PMID: 12847579
Staphylococcus aureus is a virulent pathogen that is currently a major cause of community-acquired infections, as well as infections in hospitalized patients. Morbidity and mortality due to S. aureus infections,...
6.
Xiong Y, Yeaman M, Bayer A
Drugs Today (Barc)
. 2003 Jul;
36(9):631-9.
PMID: 12847568
The U.S. Food and Drug Administration recently approved linezolid for the treatment of patients with methicillin-resistant staphylococcal and vancomycin-resistant enterococcal infections. This oxazolidinone antibacterial agent represents the first approved antibiotic...
7.
Xiong Y, Vasil M, Johnson Z, Ochsner U, Bayer A
J Infect Dis
. 2000 Mar;
181(3):1020-6.
PMID: 10720526
In Pseudomonas aeruginosa, pvdS, a key oxygen (O2)-dependent locus, regulates expression of a number of virulence genes, including toxA (which encodes exotoxin A production). To define the in vivo role...
8.
Xiong Y, Kupferwasser L, Zack P, Bayer A
Antimicrob Agents Chemother
. 1999 Jul;
43(7):1737-42.
PMID: 10390232
Optimal treatment strategies for serious infections caused by Staphylococcus aureus have not been fully characterized. The combination of a beta-lactam plus an aminoglycoside can act synergistically against S. aureus in...
9.
Xiong Y, Yeaman M, Bayer A
Antimicrob Agents Chemother
. 1999 May;
43(5):1111-7.
PMID: 10223922
Thrombin-induced platelet microbicidal protein-1 (tPMP-1) and human neutrophil defensin-1 (HNP-1) are small, cationic antimicrobial peptides. These peptides exert potent in vitro microbicidal activity against a broad spectrum of human pathogens,...
10.
Bugnon D, Potel G, Xiong Y, Caillon J, Navas D, Gras C, et al.
Eur J Clin Microbiol Infect Dis
. 1997 Aug;
16(8):575-80.
PMID: 9323468
The bactericidal activity of pefloxacin and fosfomycin alone and in combination against Pseudomonas aeruginosa was evaluated in an experimental rabbit endocarditis model after 24 h of treatment. Two strains with...